High frequency of subclonal ALK mutations in high risk neuroblastoma patients. A SIOPEN study

Bellini, AngelaBernard, VirginieLapouble, EveClement, NathaliePierron, GaelleAmbros, Inge M.Preter, Katleen deVan Roy, NadineVicha, AlesCombaret, ValérieBetts, DavidJeison, MartaAvigad, SmadarMorini, MartinaVaresio, LuigiMarques9, BarbaraMuhlethaler, AnnickNoguera, RosaBerbegall, AnaMora, Jaime Font deAmbros, Peter F.Ladenstein, RuthValteau-Couanet, DominiqueMichon, JeanDelattre, OlivierBown, NickTweddle, DeborahSchleiermache, Gudrun2016-03-042016-03-042015-11http://hdl.handle.net/10400.18/3679Introduction: In neuroblastoma (NB), activating ALK receptor tyrosine kinase point mutations are detected in 8–10% at diagnosis using conventional sequencing. To determine the potential occurrence and the prognostic impact of ALK mutations in a series of high risk NB patients we studied ALK variation frequencies using targeted deep sequencing in samples of patients enrolled in the SIOPEN HR-NBL01 studyengNeuroblastomaSIOPENALKHigh RiskDoenças GenéticasHigh frequency of subclonal ALK mutations in high risk neuroblastoma patients. A SIOPEN studyconference object